Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Reem Karmali"'
Autor:
Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K. Barta, Jason T. Romancik, Jonathon B. Cohen, Kaitlin Annunzio, Adam S. Kittai, John Reneau, Joanna Zurko, Imran A. Nizamuddin, Jane N. Winter, Leo I. Gordon, Shuo Ma, Romil Patel, Loretta Nastoupil, Sairah Ahmed, Reem Karmali
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-7 (2023)
Abstract Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases involving the central nervous system (CNS) is not well studied. We performe
Externí odkaz:
https://doaj.org/article/c3e2fa17ee934883ab1d81fbb67a6b3b
Autor:
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reaves, Montreh Tavakkoli, Kathryn Lindsey, Irl Brian Greenwell, Emily Hansinger, Colin Thomas, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Alex F. Herrera, Natalie S. Grover, Adam J. Olszewski
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-6 (2023)
Abstract Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis
Externí odkaz:
https://doaj.org/article/4835afa60d3d4971aa7119bfb3356cb7
Autor:
Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, David J. Inwards, Matthew A. Lunning, Nancy L. Bartlett, Paolo F. Caimi, Thomas D. Rodgers, Paul M. Barr, Sayan Mullick Chowdhury, Narendranath Epperla, Hiruni Mendries, Brian T. Hill, Timothy S. Oh, Reem Karmali, Julie E. Chang, Gaurav Goyal, Benjamin M. Parsons, Krista M. Isaac, Craig A. Portell, Kathleen Monahan, Malika Siker, David M. King, Timothy S. Fenske
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT confers additional benefi
Externí odkaz:
https://doaj.org/article/0727d9f9e19e46789eea66cdd1b56826
Autor:
Reem Karmali, Frederique St‐Pierre, Shuo Ma, Kelly D. Foster, Jason Kaplan, Xinlei Mi, Barbara Pro, Jane N. Winter, Leo I. Gordon
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 108-114 (2023)
Abstract Background: TAK‐659, a novel oral SYK inhibitor, has demonstrated efficacy in heavily pretreated diffuse large B‐cell lymphoma (DLBCL). We report results of a phase I single‐institution escalation study of front‐line treatment with R
Externí odkaz:
https://doaj.org/article/4ddec0d795ad48768f1172140048cc49
Publikováno v:
Cancers, Vol 16, Iss 2, p 360 (2024)
Options for treatment of incurable cancer remain scarce and are largely focused on limited therapeutic mechanisms. A new approach specific to advanced cancers is needed to identify new and effective treatments. Morbidity in advanced cancer is driven
Externí odkaz:
https://doaj.org/article/0f4cd99967df486cabf5d8e9844f0ee8
Autor:
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical pra
Externí odkaz:
https://doaj.org/article/742e9377f2884da1b8eeb0b6ff560e57
Autor:
Corinne Williams, Alexis Phillips, Vikram Aggarwal, Liron Barnea Slonim, David C. Fajgenbaum, Reem Karmali
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1359-1365 (2021)
TAFRO syndrome is defined by the presence of thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis/renal dysfunction (R), and organomegaly (O) and can be seen with idiopathic multicentric Castleman disease (iMCD) or as an isolated process
Externí odkaz:
https://doaj.org/article/765da5424ebd4c369571f06960ae50a5
Autor:
Catherine Diefenbach, Opeyemi Jegede, Richard Ambinder, Jonathon Cohen, Michael Robertson, Kevin David, Ranjana Advani, Timothy Fenske, Stefan Barta, Neil Palmisiano, Jakub Svoboda, David Morgan, Reem Karmali, Brad Kahl, Stephen M. Ansell
Publikováno v:
HemaSphere, Vol 6, Pp 46-47 (2022)
Externí odkaz:
https://doaj.org/article/747d3fe7b84b48909dc89cf4beb50fee
Publikováno v:
Case Reports in Hematology, Vol 2022 (2022)
Mantle cell lymphoma (MCL) is an aggressive, difficult to treat subtype of lymphoma, resulting in relapses and poor outcomes. Novel agents such as Bruton tyrosine kinase (BTK) inhibitors have been studied in the treatment of relapsed/refractory (R/R)
Externí odkaz:
https://doaj.org/article/6ee13fbbe6674fbd952bc7f410ec2ccc
Autor:
Alain Mina, Carlos Galvez, Reem Karmali, Mary Mulcahy, Xinlei Mi, Masha Kocherginsky, Michael J Gurley, Neelima Katam, William Gradishar, Jessica K Altman, Michael G Ison, Dean Tsarwhas, Christopher George, Jane N Winter, Leo I. Gordon, Firas H Wehbe, Leonidas C Platanias
Publikováno v:
Cancers, Vol 14, Iss 9, p 2209 (2022)
Patients with a history of malignancy have been shown to be at an increased risk of COVID-19-related morbidity and mortality. Poorer clinical outcomes in that patient population are likely due to the underlying systemic illness, comorbidities, and th
Externí odkaz:
https://doaj.org/article/d9b453b5fe7f4f12a399f363fae6ea41